The Biden administration is allocating more than $3 billion from American Rescue Plan funding towards its Antiviral Program for Pandemics, a collaboration between federal health agencies to support

BioCentury | Mar 13, 2021

Product Development

Long COVID therapies are starting to populate a sparse pipeline

Candidate treatments are split between therapies addressing symptoms versus hypothesized drivers

BioCentury | Oct 9, 2020

Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

BioCentury’s roundup of translational news

BioCentury | Aug 5, 2020

Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

COVID R&D Alliance’s adaptive trial launches with therapeutic mechanisms largely untouched in indication

BioCentury | Jul 16, 2020

Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

BioCentury | Jun 27, 2020

Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

BioCentury | Apr 7, 2020

Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Items per page:

1 - 10 of 301